vs

Side-by-side financial comparison of Bowhead Specialty Holdings Inc. (BOW) and COLLEGIUM PHARMACEUTICAL, INC (COLL). Click either name above to swap in a different company.

COLLEGIUM PHARMACEUTICAL, INC is the larger business by last-quarter revenue ($205.4M vs $155.7M, roughly 1.3× Bowhead Specialty Holdings Inc.). Bowhead Specialty Holdings Inc. runs the higher net margin — 10.3% vs 8.3%, a 2.0% gap on every dollar of revenue. On growth, Bowhead Specialty Holdings Inc. posted the faster year-over-year revenue change (26.9% vs 12.9%).

Bowhead Specialty Holdings Inc. is a specialty insurance holding company that offers a diversified portfolio of property and casualty insurance products, focusing on underserved niche market segments primarily across North America. It provides tailored risk management solutions and specialized coverage options for both commercial and individual clients.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.

BOW vs COLL — Head-to-Head

Bigger by revenue
COLL
COLL
1.3× larger
COLL
$205.4M
$155.7M
BOW
Growing faster (revenue YoY)
BOW
BOW
+14.0% gap
BOW
26.9%
12.9%
COLL
Higher net margin
BOW
BOW
2.0% more per $
BOW
10.3%
8.3%
COLL

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BOW
BOW
COLL
COLL
Revenue
$155.7M
$205.4M
Net Profit
$16.0M
$17.0M
Gross Margin
62.5%
Operating Margin
29.6%
Net Margin
10.3%
8.3%
Revenue YoY
26.9%
12.9%
Net Profit YoY
35.3%
EPS (diluted)
$0.48
$0.48

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BOW
BOW
COLL
COLL
Q1 26
$155.7M
Q4 25
$151.7M
$205.4M
Q3 25
$143.9M
$209.4M
Q2 25
$133.3M
$188.0M
Q1 25
$122.7M
$177.8M
Q4 24
$181.9M
Q3 24
$116.8M
$159.3M
Q2 24
$98.9M
$145.3M
Net Profit
BOW
BOW
COLL
COLL
Q1 26
$16.0M
Q4 25
$14.8M
$17.0M
Q3 25
$15.2M
$31.5M
Q2 25
$12.3M
$12.0M
Q1 25
$11.4M
$2.4M
Q4 24
$12.5M
Q3 24
$12.1M
$9.3M
Q2 24
$5.5M
$19.6M
Gross Margin
BOW
BOW
COLL
COLL
Q1 26
Q4 25
62.5%
Q3 25
61.7%
Q2 25
57.7%
Q1 25
54.8%
Q4 24
54.0%
Q3 24
60.8%
Q2 24
62.5%
Operating Margin
BOW
BOW
COLL
COLL
Q1 26
Q4 25
11.7%
29.6%
Q3 25
13.3%
29.7%
Q2 25
11.9%
18.7%
Q1 25
11.8%
12.2%
Q4 24
20.9%
Q3 24
13.5%
21.9%
Q2 24
7.5%
32.7%
Net Margin
BOW
BOW
COLL
COLL
Q1 26
10.3%
Q4 25
9.8%
8.3%
Q3 25
10.5%
15.0%
Q2 25
9.3%
6.4%
Q1 25
9.3%
1.4%
Q4 24
6.9%
Q3 24
10.4%
5.9%
Q2 24
5.6%
13.5%
EPS (diluted)
BOW
BOW
COLL
COLL
Q1 26
$0.48
Q4 25
$0.44
$0.48
Q3 25
$0.45
$0.84
Q2 25
$0.36
$0.34
Q1 25
$0.34
$0.07
Q4 24
$0.36
Q3 24
$0.36
$0.27
Q2 24
$0.20
$0.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BOW
BOW
COLL
COLL
Cash + ST InvestmentsLiquidity on hand
$97.2M
$386.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$457.9M
$301.7M
Total Assets
$2.5B
$1.7B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BOW
BOW
COLL
COLL
Q1 26
$97.2M
Q4 25
$193.5M
$386.7M
Q3 25
$197.9M
$285.9M
Q2 25
$114.8M
$222.2M
Q1 25
$88.0M
$197.8M
Q4 24
$162.8M
Q3 24
$132.9M
$120.0M
Q2 24
$180.3M
$271.6M
Total Debt
BOW
BOW
COLL
COLL
Q1 26
Q4 25
$146.4M
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
BOW
BOW
COLL
COLL
Q1 26
$457.9M
Q4 25
$448.3M
$301.7M
Q3 25
$430.2M
$274.8M
Q2 25
$407.2M
$232.2M
Q1 25
$391.0M
$234.4M
Q4 24
$228.8M
Q3 24
$364.7M
$234.3M
Q2 24
$339.9M
$216.6M
Total Assets
BOW
BOW
COLL
COLL
Q1 26
$2.5B
Q4 25
$2.4B
$1.7B
Q3 25
$2.1B
$1.6B
Q2 25
$1.9B
$1.6B
Q1 25
$1.8B
$1.6B
Q4 24
$1.7B
Q3 24
$1.5B
$1.6B
Q2 24
$1.4B
$1.1B
Debt / Equity
BOW
BOW
COLL
COLL
Q1 26
Q4 25
0.33×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BOW
BOW
COLL
COLL
Operating Cash FlowLast quarter
$123.0M
Free Cash FlowOCF − Capex
$122.4M
FCF MarginFCF / Revenue
59.6%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
7.25×
TTM Free Cash FlowTrailing 4 quarters
$327.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BOW
BOW
COLL
COLL
Q1 26
Q4 25
$331.6M
$123.0M
Q3 25
$114.7M
$78.4M
Q2 25
$109.0M
$72.4M
Q1 25
$47.7M
$55.4M
Q4 24
$84.6M
Q3 24
$119.4M
$-9.0M
Q2 24
$67.4M
Free Cash Flow
BOW
BOW
COLL
COLL
Q1 26
Q4 25
$326.0M
$122.4M
Q3 25
$113.5M
$78.3M
Q2 25
$107.4M
$72.4M
Q1 25
$46.5M
$54.6M
Q4 24
$84.1M
Q3 24
$118.4M
$-9.2M
Q2 24
$67.1M
FCF Margin
BOW
BOW
COLL
COLL
Q1 26
Q4 25
214.9%
59.6%
Q3 25
78.8%
37.4%
Q2 25
80.6%
38.5%
Q1 25
37.9%
30.7%
Q4 24
46.2%
Q3 24
101.4%
-5.8%
Q2 24
46.2%
Capex Intensity
BOW
BOW
COLL
COLL
Q1 26
Q4 25
3.7%
0.3%
Q3 25
0.9%
0.1%
Q2 25
1.2%
0.0%
Q1 25
1.0%
0.4%
Q4 24
0.3%
Q3 24
0.9%
0.2%
Q2 24
0.2%
Cash Conversion
BOW
BOW
COLL
COLL
Q1 26
Q4 25
22.34×
7.25×
Q3 25
7.56×
2.49×
Q2 25
8.83×
6.05×
Q1 25
4.18×
22.92×
Q4 24
6.75×
Q3 24
9.88×
-0.96×
Q2 24
3.44×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons